Brain scans may reveal who will benefit from common antidepressant

This study aims to find brain-based markers that can predict how individuals with major depression will respond to the antidepressant sertraline (Zoloft). Researchers will use fMRI and EEG brain scans to measure brain activity and connections before treatment. Fifty adults with chronic or recurrent depression will take sertraline for 8 weeks, and their symptom changes will be linked to their brain scan patterns. The goal is to personalize depression treatment by identifying which patients are most likely to benefit from this medication.